MORE THAN a century ago, the effects of botulinum toxin were first described as botulism after reports of severe neuropathic illness from eating spoiled sausage. It is ironic that the causative agent of such toxicity has in recent decades become a powerful therapeutic tool for the treatment of a variety of neurologic disorders. Application of botulinum toxin for aesthetic purposes is even more confounding. Botulinum toxin is an exotoxin that is produced by the anaerobic bacterium Clostridium botulinum. It acts by inhibiting acetylcholine release from the neuromuscular junction, causing a flaccid paralysis or muscle weakening in injected muscles. This effect has been found to minimize or eliminate facial wrinkles that are caused, in part or in whole, by hyperactivity of the underlying musculature. Botulinum toxin injections have indeed become very popular for the treatment of hyperkinetic facial wrinkles in the glabela, forehead, and periorbital regions.
Two antigenically distinct serotypes of botulinum toxin are available in the U.S. marketplace: botulinum toxin type A (BTX-A; Botox; Allergan, Irvine, CA) and botulinum toxin type B (BTX-B; Myobloc; San Diego, CA). A different type A preparation is available in Europe as Dysport (Ipsen Ltd., Berkshire, UK). The U.S. Food and Drug Administration (FDA) approved BTX-A, the first toxin to be investigated, in 1989 for the treatment of blepharospasm, strabismus, and hemifacial spasm and in 2002 for the treatment of moderate to severe glabelar wrinkles. For many years, BTX-A was the only botulinum toxin that was available. However, in 2000, BTX-B was FDA approved for treating cervical dystonia. Although not currently approved for cosmetic use, BTX-B has been used off-label to improve facial wrinkles, as well as for many other conditions (e.g., headache, pain, spasticity).
BTX-B differs from BTX-A in many aspects (Table 1) . For one, it has been developed as a purified liquid preparation buffered at a pH of 5.6. Therefore, unlike BTX-A, which is a lyophilized powder preparation, BTX-B does not require reconstitution, making it more convenient and easier to use. Its slightly acidic formulation ensures that the protein complex remains stable and intact during injection, but it may be more painful on injection. BTX-B can be conveniently stored in a refrigerator, with stability for 3 years, and it is also stable at room temperature for at least 9 months. 1 As BTX-B is a liquid formulation, its manufacture does not involve the process of lyophilization or vacuum drying, which has been associated with variable loss of potency from batch to batch and with protein denaturation. 2 On a molecular level, BTX-B binds to completely different acceptors on neuronal cells and cleaves the SNARE protein synaptobrevin (whereas BTX-A cleaves SNAP-25) to exert ultimately its paralytic effect on injected muscles. 3 BTX-B is available in three vial presentations of 2,500, 5,000, and 10,000 U. Of importance, each vial is overfilled and therefore contains more BTX-B than stated on the label: The vial containing 2500 U/0.5 mL actually has 4,100 U in 0.82 mL, and the 5,000 U/1 mL vial actually contains 6,800 U in 1.36 mL, and the 10,000 U/2 mL vial contains 12,650 U in 2.53 mL.
Development of BTX-B began in the early 1990s
with interest in its use for treating patients with cervical dystonia, a disorder characterized by excessive contractions of the cervical and/or shoulder muscles. Several large randomized, placebo-controlled clinical trials have demonstrated that BTX-B is safe and effective in this patient group. 4-6 Improvement in signs and symptoms of cervical dystonia tended to increase and to last longer with increasing doses. In the two pivotal trials, researchers enrolled patients who were BTX-A responsive (N 5 109) 4 or who had confirmed BTX-A resistance (N 5 77). 5 Patients were randomized to receive intramuscular injections of BTX-B (at doses of up to 10,000 U) or placebo into two to four affected muscles of the neck and/or shoulder. In both studies, significant improvement in cervical dystonia was noted at 4 weeks, with treatment effects lasting from 12 to 16 weeks. Thus, in studies of patients with cervical dystonia, the effects of BTX-B are similar to those of BTX-A. Adverse effects included dry mouth and dysphagia, which were mild to moderate in intensity and were self-limiting.
In recent years, BTX-B has been investigated for treating hyperkinetic facial wrinkles (although there are currently no efforts to obtain FDA approval in the setting of cosmetic dermatology). The author has evaluated three different doses of BTX-B for glabelar wrinkles in two separate, preliminary, open-label, dose-ranging studies. 7, 8 Subjects received six injections, two in the procerus muscle and four in the corrugator muscles (two medial and two lateral). In the first study, 30 subjects received a total BTX-B dose of 1,800 U (300 U/injection site), which correlates to a ratio of 75 U of BTX-B to 1 U of BTX-A. 7 In the second study, 16 subjects received 2,400 U of BTX-B (400 U/injection site) and 18 subjects received 3,000 U (500 U per injection site). 8 Dose correlations of BTX-B to BTX-A were 100:1 and 125:1 for 2,400 and 3,000 U, respectively. Because of differences in potency assays used and species sensitivity to each toxin, it is important to understand that the products have their own individual efficacy and safety profiles and are not interchangeable based on a dose ratio. Rather, these doses were used as reasonable starting points based on previous trials 9 and comparing the doses used for BTX-A and BTX-B for cervical dystonia.
All subjects experienced significant improvement in glabelar wrinkles, as demonstrated by both patient and physician assessments. BTX-B had a very rapid onset of effect, with noticeable improvement in facial wrinkles within 1 to 2 days. This onset of effect appears to be faster than that observed with BTX-A; however, at the doses used, BTX-B had a shorter duration of effect as compared with that generally reported for BTX-A (schematic representation in Figure 1 ). Mean durations were 8.0, 9.6, and 10.4 weeks after treatment with 1,800, 2,400, and 3,000 U, respectively. In the highest dose group, the duration of effect ranged from 8 to 13 weeks. Adverse effects were minimal in all treatment groups and were similar to those reported with BTX-A. In the highest dose group, headache and lid ptosis were reported in one patient. Overall, BTX-B was very safe and was not associated with an increase in adverse effects at the higher doses. These results coincide with those from other openlabel studies evaluating BTX-B for facial wrinkles. [10] [11] [12] The author noted that based on clinical experience with BTX-A, BTX-B appears to diffuse more evenly across the injected muscles, yielding a more uniform paralysis and a smoother aesthetic effect. The smaller size of the BTX-B molecule (700 vs. 900 kDa with BTX-A) may attribute to its enhanced diffusion characteristics. Further clinical experience with continuing use will help to define this parameter. In addition, more clinical studies are needed to determine the optimal dose of BTX-B in the treatment of glabelar wrinkles. Preliminary studies suggest that the duration of effect is dose related (as do prior studies in cervical dystonia). Therefore, for glabelar wrinkles, it is anticipated that doses higher than 3,000 U of BTX-B will result in a longer duration of effect. The author is conducting another study evaluating 3,600 U of BTX-B for glabelar wrinkles, using three, instead of six, injections. Because of the diffusion characteristics of BTX-B, it is felt that the same overall effects can be obtained using a smaller number of injections.
Overall, BTX-B is a safe and effective method to eliminate glabelar wrinkles nonsurgically. Based on preliminary data, BTX-B has several potential uses: (1) patients requesting rapid onset of effect (BTX-B appears to have a faster onset than does BTX-A, by 1 to 2 days); (2) patients requesting a more ''uniform freeze'' (as may occur for patients desiring forehead injections; BTX-B appears to provide a more even paralysis than does BTX-A); (3) touch-up procedures (because BTX-B solution does not need to be reconstituted and can be easily stored, it may be more readily available for patients desiring touch-ups); (4) patients with resistance to BTX-A. Because the toxins are antigenically distinct, BTX-A-resistant patients can benefit from treatment with BTX-B. This has been demonstrated in a study of BTX-B in BTX-A-resistant patients with cervical dystonia. 5 It should be noted, however, that resistance has not been reported at the low doses used for facial injections. Given these areas of potential uses and advantages, BTX-B is a welcome addition to the therapeutic armamentarium in aesthetic medicine, and further studies to clarify its duration of clinical effect and dosing are in order.
between toxin dose and duration of clinical response. The acidic pH (5.6) of Myobloc accounts for the discomfort upon injection, and some have suggested the addition of sodium bicarbonate as a buffer or saline containing the preservative benzyl alcohol, however, potentially at the risk of diminishing potency. The issue of diffusion may account for the increased sensation of muscle tightness and, furthermore, determines the appropriate injection sites that will prevent spread into adjacent facial musculature. Because of the smaller molecular weight of Myobloc (700 kDa) compared with Botox (900 kDa), it is conceivable that there is increased potential of spread of the B serotype with consequent paresis of uninjected anatomy.
Perhaps ultimately the defining characteristic that will determine toxin selection, as Dr. Sadick suggests, will be dosing and the development of clinical resistance due to production of neutralizing antibodies. To date, immunoresistance with Botox has only sporadically and anecdotally been addressed, and its actual realization seems remote with the low volumes and small amounts of neurotoxin protein administered (5 ng/100 U vial of Botox, 25 ng/2,500 U vial of Myobloc). However, with the higher volumes of Myobloc that are generally required to achieve comparable response to Botox, not only does it appear that it may prove to be a more costly procedure for the patient, but with these larger protein loads there will be an increased higher risk of development of neutralizing antibodies.
Again, Dr. Sadick is to be commended on providing a large clinical trial with new and relevant information on chemodenervation. In the final analysis, it should be reiterated that these two species-sensitive toxins have distinct pharmacologies and hence perhaps their own unique set of indications and safety profiles. Although a conversion ratio is not yet well-established nor might it be appropriate, the addition of newer agents will provide physicians acceptable alternatives to effectively improve patients' appearance, and the therapeutic indications will enhance their quality of life. Clearly, as more people are competing to provide this service and more toxins become available, it is incumbent on us to have precise scientific data not only to enable physicians to communicate their data but to best treat patients safely.
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